Ercules Comunicazioni
Ercules Comunicazioni is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
(20275) An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
(21177) A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Ercules Comunicazioni?
The 2026-10-09 snapshot links Ercules Comunicazioni to 4 distinct CTIS trials. Recorded services include Development of Recruitment and Retention materials (R&R), Patient recruitment services, production of recruitment and retention material, To create recruitment and retention materials. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ercules Comunicazioni?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Nephrology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ercules Comunicazioni conducted?
The linked trials record locations in 15 countries, including Bulgaria, Czechia, Spain, Italy, Portugal. These are trial locations, not confirmed office locations or countries where Ercules Comunicazioni delivered services.
What can this page tell me about Ercules Comunicazioni's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Ercules Comunicazioni. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ercules Comunicazioni S.r.l.